Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of TAF vs TDF in HBeAg-negative chronic hepatitis B
2013-000626-63Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Tenofovir alafenamide 25 mg QD with Tenofovir disoproxil fumarate 300 mg QD (2 arms). Primary endpoint: HBV DNA suppression at Week 48. Started Sep 2013; status: completed.
02
Drugs
tenofovir disoproxil fumaratetenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2013-000626-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000626-63.